Prescription drug · ANDA
Bortezomib NDC 72603-270
Bortezomib 3.5 mg/1 · Injection, Powder, Lyophilized, For solution · Intravenous, Subcutaneous · NorthStar RxLLC
NDC codes
FDA NDC Directory| Package NDC | 11-digit (billing) | Package | Copy |
|---|---|---|---|
| 72603-270-01 | 7260302700172603027001 | 1 VIAL, SINGLE-DOSE in 1 CARTON (72603-270-01) / 1 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION in 1 VIAL, SINGLE-DOSEMarketed from Nov 1, 2024 |
How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules
Product information
- Brand name (proprietary)
- Bortezomib
- Generic name (nonproprietary)
- bortezomib
- Active ingredients
- Bortezomib — 3.5 mg/1
- Dosage form
- Injection, Powder, Lyophilized, For solution
- Route
- Intravenous, Subcutaneous
- Labeler
- NorthStar RxLLCNDC labeler code 72603
- Product type
- Prescription drug
- Marketing category
- ANDA — Abbreviated New Drug Application (generic)Application ANDA 202963
- Marketing start
- Listing expires
- Other FDA classes
- Proteasome Inhibitors (Mechanism)
- Identifiers
- Product ID 72603-270_27ad9395-c6d2-f500-ab18-07278b7c7b0eSPL ID 27ad9395-c6d2-f500-ab18-07278b7c7b0eSPL set ID 3f02670b-5683-780c-9d38-5d8f0ef43a14RxCUI 402243UNII 69G8BD63PPUPC 0372603270013
- Pharmacologic class
- Proteasome Inhibitor
Billing references
What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.
- HCPCS codeNo match
No drug-specific HCPCS code in Med-Code's directory for this product. The directory is curated and not complete — check the current CMS HCPCS file before billing.
- Administration
Drug administration (CPT 96360–96549)
When a clinician administers the drug, the administration is reported separately. Codes in this range cover hydration, therapeutic injections and infusions, and chemotherapy or other complex drug administration. The right code depends on route, duration and drug type, and self-administered drugs are not billed this way.
- NDC on a medical claim
N472603027001followed by a unit qualifier and the quantityPackage 72603-0270-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier
Product label
Current FDA label (SPL), effective .
Indications (excerpt from the label)
Bortezomib for injection is a proteasome inhibitor indicated for: treatment of adult patients with multiple myeloma ( 1.1 ) treatment of adult patients with mantle cell lymphoma ( 1.2 ) 1.1 Multiple Myeloma Bortezomib for injection is indicated for the treatment of adult patients with multiple myeloma. 1.2 Mantle Cell Lymphoma Bortezomib for injection is indicated for the treatment of adult patients with mantle cell lymphoma.
Excerpt only. Read the full label for complete information.
About NDC 72603-270
- What is NDC 72603-270?
- 72603-270 is the product NDC for Bortezomib, Bortezomib 3.5 mg/1 injection, powder, lyophilized, for solution, listed with the FDA by NorthStar RxLLC. It has 1 package NDC, shown above in 10- and 11-digit form.
- What drug is associated with this NDC?
- Bortezomib.
- What is the active ingredient?
- Bortezomib.
- Who is the labeler?
- NorthStar RxLLC, NDC labeler code 72603. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.
- What other NDCs exist for Bortezomib?
- 29 other product NDCs are listed under this name. See all Bortezomib NDCs.
- Is there a related HCPCS / J-code?
- Not in Med-Code's curated HCPCS directory. See Billing references above.
Related NDCs: other Bortezomib products
Other finished products listed under the same name: strengths, forms and labelers.
| Product | Strength | Form · route | Labeler | Product NDC | Package NDCs (11-digit) |
|---|---|---|---|---|---|
| Bortezomib | Bortezomib 3.5 mg/1 | Injection, Powder, Lyophilized, For solutionIntravenous, Subcutaneous | Avenacy, LLC | 83634-208 | 83634-0208-10 |
| Bortezomib | Bortezomib 1 mg/1 | Injection, Powder, Lyophilized, For solutionIntravenous, Subcutaneous | Gland Pharma Limited | 68083-650 | 68083-0650-01 |
| Bortezomib | Bortezomib 2.5 mg/1 | Injection, Powder, Lyophilized, For solutionIntravenous, Subcutaneous | Gland Pharma Limited | 68083-651 | 68083-0651-01 |
| Bortezomib | Bortezomib 3.5 mg/1 | Injection, Powder, Lyophilized, For solutionIntravenous, Subcutaneous | Ningbo Shuangcheng Pharmaceutical Co., Ltd. | 75007-501 | 75007-0501-3175007-0501-32 |
| Bortezomib | Bortezomib 3.5 mg/1 | Injection, Powder, Lyophilized, For solutionIntravenous, Subcutaneous | Sagent Pharmaceuticals | 25021-262 | 25021-0262-10 |
| Bortezomib | Bortezomib 3.5 mg/3.5mL | Injection, Powder, Lyophilized, For solutionIntravenous, Subcutaneous | Somerset Therapeutics LLC | 70069-836 | 70069-0836-01 |
| Bortezomib | Bortezomib 3.5 mg/1.4mL | InjectionIntravenous, Subcutaneous | Shilpa Medicare Limited | 63759-3032 | 63759-3032-01 |
| Bortezomib | Bortezomib 3.5 mg/1 | Injection, Powder, Lyophilized, For solutionIntravenous, Subcutaneous | Camber Pharmaceuticals, Inc. | 31722-303 | 31722-0303-31 |
| Bortezomib | Bortezomib 3.5 mg/3.5mL | Injection, Powder, Lyophilized, For solutionIntravenous, Subcutaneous | Sintetica US LLC | 83090-008 | 83090-0008-01 |
| Bortezomib | Bortezomib 1 mg/1 | InjectionIntravenous | MAIA Pharmaceuticals, Inc. | 70511-161 | 70511-0161-05 |
Other NDCs under ANDA 202963
Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.
| Product | Strength | Form · route | Labeler | Product NDC |
|---|---|---|---|---|
| Bortezomib | Bortezomib 3.5 mg/1 | Injection, Powder, Lyophilized, For solutionIntravenous, Subcutaneous | Dr.Reddy's Laboratories, Inc. | 43598-426 |